Replies to post #513 on The Moon Phase

[PoemStone]

CSII. ST. PAUL, Minn.--(BUSINESS WIRE)--

Cardiovascular Systems, Inc. (CSII):

Revenues rose to $23.3 million in the fiscal 2013 first quarter, up 25 percent over the first quarter of fiscal 2012
Office-based lab revenues continued to grow at a double-digit consecutive quarter rate over the fourth quarter of fiscal 2012
Stealth 360°® revenues grew to 90 percent of total device revenues
Presentations at TCT conference reveal that moderate/severe calcification in coronary arteries is associated with higher complication rates, including a significantly higher incidence of death, highlighting a critical need for new treatment technologies
ORBIT II coronary trial endpoints are designed to demonstrate CSI technology’s ability to meet this need
Trial enrollment is 93 percent completed, with only 33 patients remaining
CONFIRM series, presented at VIVA’s late-breaking data session, shows that CSI’s orbital atherectomy system safely and effectively removes plaque in calcified peripheral lesions

http://finance.yahoo.com/news/cardiovascular-systems-reports-fiscal-2013-200000157.html